hypothermia. The company has developed a method that will improve the release of drugs and relieve symptoms. It is currently preparing for a phase I study that will begin in 2023. To take the next step in development, a financing round of approximately 3 million Euros is being conducted. CEO Sahil Gupta visited BioStock's studio to tell us more.
Watch the interview with Prolevi Bios vd Sahil Gupta, in English, below.